Prosecution Insights
Last updated: April 19, 2026

Examiner: BATES, KEENAN ALEXANDER

Tech Center 1600 • Art Units: 1631

This examiner grants 46% of resolved cases

Performance Statistics

46.3%
Allow Rate
-13.7% vs TC avg
142
Total Applications
+70.8%
Interview Lift
1205
Avg Prosecution Days
Based on 54 resolved cases, 2023–2026

Rejection Statute Breakdown

6.3%
§101 Eligibility
24.3%
§102 Novelty
31.9%
§103 Obviousness
28.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18939389 SYSTEM FOR HYPOTHERMIC TRANSPORT Non-Final OA Paragonix Technologies, Inc.
18939375 METHODS FOR COOLING AN ORGAN Non-Final OA Paragonix Technologies, Inc.
17765796 MICROGLIA SPECIFIC PROMOTERS AND METHODS OF USE THEREFORE Non-Final OA Dana-Farber Cancer Institute, Inc.
17287972 ONCOLYTIC VIROTHERAPY AND IMMUNOTHERAPY Final Rejection Baylor College of Medicine
18011365 NOVEL GAIN-OF-FUNCTION MUTANT OF BMPR2 GENE AND USE THEREOF Final Rejection SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION
17601581 COMPOSITIONS AND METHODS FOR IN UTERO GENE EDITING FOR MONOGENIC LUNG DISEASE Non-Final OA THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
18892177 METHODS FOR CREATING LINKAGE OF MULTIPLE VIRAL VECTORS FOR INTRACELLULAR DELIVERY Final Rejection Battelle Memorial Institute
18029516 BIOORTHOGONAL REPORTER GENE SYSTEM Non-Final OA Technische Universität München
17564949 Cell Culture System Final Rejection Saint-Gobain Performance Plastics Corporation
18020734 METHOD FOR THE TREATMENT OF WWOX ASSOCIATED DISEASES Non-Final OA YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
17275084 AUTOMATED GENERATION AND ANALYSIS OF ORGANOIDS Non-Final OA Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
18041447 Methods of Protecting RNA Non-Final OA Pfizer Inc.
17669874 PANCREATIC DIFFERENTIATION Final Rejection Vertex Pharmaceuticals Incorporated
18233146 CELL EXPANSION SYSTEM Non-Final OA Terumo BCT, Inc.
18016251 SONOGENETIC STIMULATION OF CELLS EXPRESSING TRPA1 Non-Final OA Salk Institute for Biological Studies
18418855 VECTOR FOR CANCER TREATMENT Non-Final OA CANCER RESEARCH TECHNOLOGY LIMITED
17721455 VECTOR FOR CANCER TREATMENT Final Rejection CANCER RESEARCH TECHNOLOGY LIMITED
17598814 IMMUNODEFICIENT RODENT Non-Final OA CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS
18161467 CELLULAR REPROGRAMMING OF HUMAN ADIPOCYTES Non-Final OA MIAMI UNIVERSITY
17740665 METHODS OF MINIMIZING NEUROTOXICITY ASSOCIATED WITH CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY Non-Final OA Legend Biotech USA Inc.
17632026 DUX4 EXPRESSING CELLS AND USES THEREOF Final Rejection Sana Biotechnology, Inc.
17309261 IN VITRO ASSAY FOR DETECTING ENHANCERS AND INHIBITORS OF ADENO ASSOCIATED VIRUS (AAV) VECTOR TRANSDUCTION AND/OR DETECTING OR QUANTITATING ANTI-AAV BINDING ANTIBODIES Final Rejection SPARK THERAPEUTICS, INC.
18220461 MEDIUM FOR BREEDING HERMETIA ILLUCENS LARVA THAT PRODUCES HIGHLY ACTIVE ANTIMICROBIAL PEPTIDE (AMP), BREEDING METHOD, AND EXTRACTION METHOD OF AMP Non-Final OA Agricultural Products Processing Research Institute, CATAS
17982805 PHARMACEUTICAL COMPOSITION AND USE THEREOF FOR REPAIRING DAMAGED LIVER, TREATING DISEASE ASSOCIATED WITH DAMAGED LIVER AND IMPROVING FUNCTIONS OF LIVER Final Rejection TAIWAN MITOCHONDRION APPLIED TECHNOLOGY CO., LTD.
18219649 Engineered probiotic platform for in-situ conversion of sugars to functional ingredients Non-Final OA GutMind Corp
18217863 TRANSPOSON-BASED VECTORS AND USES Non-Final OA Just-Evotec Biologics, Inc.
17427720 NEW USE OF STEM CELL GENERATOR IN PREPARATION OF BONE DEFECT REPAIR MATERIALS Final Rejection EAST CHINA UNIVERSITY OF SCIENCE AND TECHNOLOGY
17424140 MICROENVIRONMENT SENSORS TO REGULATE ENGINEERED GENE EXPRESSION Non-Final OA Seattle Children's Hospital (dba Seattle Children's Research Institute)
18168426 COMPOSITIONS AND METHODS FOR THE TARGETING OF SOD1 Non-Final OA Scribe Therapeutics Inc.
18037986 VECTOR SYSTEM FOR DELIVERY OF MULTIPLE POLYNUCLEOTIDES AND USES THEREOF Non-Final OA Umoja Biopharma, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month